Related Experiment Video
Updated: Aug 9, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Telling the difference between frontotemporal dementia and Alzheimer's disease
1Memory Clinic, Department of Neurology, University Hospital, Lille, France. pasquier@chru.lille.fr
Current Opinion in Psychiatry
|April 28, 2006
Summary
Accurate diagnosis of dementia is crucial for patient management. While frontotemporal dementia is often misdiagnosed as Alzheimer's disease, advancements in understanding cognitive and emotional impairments aid in distinguishing these conditions.
Area of Science:
- Neurology
- Neuroscience
- Psychiatry
Background:
- Precise dementia diagnosis is vital for effective patient management, prognosis, and genetic counseling.
- Frontotemporal dementia (FTD) is frequently underdiagnosed or misdiagnosed as Alzheimer's disease (AD).
- Increasing research focuses on differentiating FTD and AD syndromes.
Purpose of the Study:
- To review the current understanding and diagnostic challenges in differentiating frontotemporal dementia from Alzheimer's disease.
- To highlight the importance of accurate diagnosis for patient and family counseling regarding prognosis and management.
- To explore recent advancements in distinguishing these neurodegenerative conditions.
Main Methods:
- Review of recent scientific literature and studies comparing FTD and AD.
- Analysis of progress in neuropsychological testing and understanding of brain functioning.
- Evaluation of the role of biomarkers in differential diagnosis.
Main Results:
- Neuropsychological testing and insights into emotion, insight, behavior, and creativity have improved syndrome differentiation.
- Biomarkers have not yet enhanced diagnostic accuracy for clinicians or distinguished between FTD subtypes.
- Understanding cognitive and emotional deficits is key to managing patients with FTD and AD.
Conclusions:
- Enhanced knowledge of cognitive and emotional impairments in FTD and AD is essential for patient care.
- Accurate diagnosis facilitates better information delivery to patients and families, improving understanding and management.
- Continued research is needed to refine diagnostic tools and differentiate between dementia subtypes.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...